MicroRNA-375: potential cancer suppressor and therapeutic drug | Zendy

Jiahui Wei | Zendy; Yiran Lu | Zendy; Ruiqing Wang | Zendy; Xiangzhu Xu | Zendy; Qing Liu | Zendy; Song He | Zendy; Huihao Pan | Zendy; Xinmiao Liu | Zendy; Bao Yuan | Zendy; YuQiang Ding | Zendy; Jiabao Zhang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MicroRNA-375: potential cancer suppressor and therapeutic drug

Author(s) -

Jiahui Wei,

Yiran Lu,

Ruiqing Wang,

Xiangzhu Xu,

Qing Liu,

Song He,

Huihao Pan,

Xinmiao Liu,

Bao Yuan,

YuQiang Ding,

Jiabao Zhang

Publication year - 2021

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20211494

Subject(s) - suppressor , drug , microrna , cancer , cancer research , cancer drugs , computational biology , biology , pharmacology , genetics , gene

MiR-375 is a conserved noncoding RNA that is known to be involved in tumor cell proliferation, migration, and drug resistance. Previous studies have shown that miR-375 affects the epithelial-mesenchymal transition (EMT) of human tumor cells via some key transcription factors, such as Yes-associated protein 1 (YAP1), Specificity protein 1 (SP1) and signaling pathways (Wnt signaling pathway, nuclear factor κB (NF-κB) pathway and transforming growth factor β (TGF-β) signaling pathway) and is vital for the development of cancer. Additionally, recent studies have identified microRNA (miRNA) delivery system carriers for improved in vivo transportation of miR-375 to specific sites. Here, we discussed the role of miR-375 in different types of cancers, as well as molecular mechanisms, and analyzed the potential of miR-375 as a molecular biomarker and therapeutic target to improve the efficiency of clinical diagnosis of cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research